AI Engines For more Details: Perplexity Kagi Labs You
Opioid Withdrawal Syndrome: Lofexidine is specifically indicated for the management of symptoms of opioid withdrawal syndrome in adults. These symptoms may include anxiety, agitation, muscle aches, sweating, diarrhea, abdominal cramping, nausea, vomiting, and insomnia. Lofexidine helps to alleviate these symptoms by calming the sympathetic nervous system, which is overactive during withdrawal.
Opioid Dependence Treatment: Lofexidine is sometimes used as part of a comprehensive treatment plan for opioid dependence or addiction. It can be used during the detoxification phase to help individuals transition from opioid use to abstinence more comfortably.
Post-Acute Withdrawal Syndrome (PAWS): Some individuals may experience lingering symptoms of opioid withdrawal known as post-acute withdrawal syndrome (PAWS). Lofexidine may help manage these symptoms during the early recovery phase.
Adjunctive Therapy: Lofexidine may be used as an adjunctive therapy alongside other medications or behavioral therapies in the treatment of opioid use disorder.
Hypertension: Lofexidine's mechanism of action as an alpha-2 adrenergic agonist also leads to a decrease in blood pressure. While this effect is beneficial during opioid withdrawal, it can also be used in the treatment of hypertension (high blood pressure) when prescribed and monitored by a healthcare professional.
Anxiety Disorders: Lofexidine's calming effects may be beneficial for individuals with anxiety disorders, although it is not typically prescribed for this purpose and other medications are more commonly used.
Insomnia: Lofexidine's ability to reduce sympathetic nervous system activity may help improve sleep quality in individuals experiencing insomnia, although it is not typically prescribed as a primary treatment for this condition.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Anaerobutyricum hallii | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Actinomyces oris | species | Decreases |
| 0 | 1 | Corynebacterium durum | species | Decreases |
| 0 | 1 | Actinomyces naeslundii | species | Decreases |
| 0 | 1 | Olsenella sp. oral taxon 807 | species | Decreases |
| 0 | 1 | Bacillus paralicheniformis | species | Decreases |
| 0 | 1 | Streptococcus sanguinis | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Adlercreutzia hattorii | species | Decreases |
| 0 | 1 | Blautia obeum | species | Decreases |
| 0 | 1 | Phoenicibacter congonensis | species | Decreases |
| 0 | 1 | Faecalibacillus intestinalis | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Actinomyces sp. oral taxon 171 | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Wansuia hejianensis | species | Decreases |
| 0 | 1 | Coprococcus comes | species | Decreases |
| 0 | 1 | Streptococcus gordonii | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 0 | 1 | Streptococcus mutans | species | Decreases |
| 0 | 1 | Romboutsia sp. 13368 | species | Decreases |
| 0 | 1 | Intestinibaculum porci | species | Decreases |
| 0 | 1 | Actinomyces sp. oral taxon 169 | species | Decreases |
| 0 | 1 | Romboutsia sp. CE17 | species | Decreases |
| 0 | 1 | Turicibacter bilis | species | Decreases |
| 0 | 1 | Ligilactobacillus ruminis | species | Decreases |
| 0 | 1 | Subdoligranulum variabile | species | Decreases |
| 0 | 1 | Komagataeibacter oboediens | species | Decreases |
| 0 | 1 | [Ruminococcus] torques | species | Decreases |
| 0 | 1 | Olsenella uli | species | Decreases |
| 0 | 1 | Mogibacterium diversum | species | Decreases |
| 0 | 1 | Eubacterium ventriosum | species | Decreases |
| 0 | 1 | Adlercreutzia equolifaciens | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0 | 0 | |
| ADHD | 0.1 | 0.1 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0 | 0 |
| Allergies | 1.1 | 0 | 0 |
| Allergy to milk products | 0.1 | -0.1 | |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 0.6 | 0.3 | 1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Ankylosing spondylitis | 0.3 | 0.3 | |
| Anorexia Nervosa | 0 | 0 | 0 |
| Asthma | 0.4 | 0.1 | 3 |
| Atherosclerosis | 0.2 | 0 | 0 |
| Atrial fibrillation | 0.3 | 0 | 0 |
| Autism | 0.7 | 0.4 | 0.75 |
| Autoimmune Disease | 0 | 0 | 0 |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0 | 0 | |
| Brain Trauma | 0 | 0 | 0 |
| Cancer (General) | 0 | 0 | |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.3 | -0.3 | |
| Cerebral Palsy | 0 | 0 | 0 |
| Chronic Fatigue Syndrome | 0.1 | 1.6 | -15 |
| Chronic Kidney Disease | 0.6 | 0.1 | 5 |
| Chronic Lyme | 0.1 | 0 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0 | 0 | |
| Cognitive Function | 0.3 | 0 | 0 |
| Colorectal Cancer | 0 | 0.1 | 0 |
| Constipation | 0 | 0 | |
| Coronary artery disease | 0.1 | 0.1 | 0 |
| COVID-19 | 0.8 | 1.7 | -1.13 |
| Crohn's Disease | 0.4 | 0.5 | -0.25 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0 | 0 | |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 0.4 | 0.6 | -0.5 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0 | 0 | |
| Endometriosis | 0.3 | 0 | 0 |
| Epilepsy | 0 | 0 | 0 |
| erectile dysfunction | 0 | 0 | |
| Fibromyalgia | 0.4 | 0.1 | 3 |
| Functional constipation / chronic idiopathic constipation | 0 | 0.1 | 0 |
| gallstone disease (gsd) | 0.3 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0 | 0 | |
| Graves' disease | 0 | 0.4 | 0 |
| Gulf War Syndrome | 0 | 0 | |
| Hashimoto's thyroiditis | 0.6 | 0.1 | 5 |
| Heart Failure | 0.2 | 0.2 | 0 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| High Histamine/low DAO | 0 | 0 | 0 |
| hyperglycemia | 0.1 | 0 | 0 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 0.4 | 0.1 | 3 |
| Hypothyroidism | 0 | 0 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.1 | 0 | 0 |
| Inflammatory Bowel Disease | 0.1 | 0.5 | -4 |
| Insomnia | 0.4 | 0 | 0 |
| Irritable Bowel Syndrome | 0.5 | 0 | 0 |
| ischemic stroke | 0 | 0 | 0 |
| Liver Cirrhosis | 0.4 | 0.4 | 0 |
| Long COVID | 0.6 | 0.7 | -0.17 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.4 | -0.4 | |
| Mast Cell Issues / mastitis | 0 | 0 | |
| ME/CFS with IBS | 0 | 1.3 | 0 |
| ME/CFS without IBS | 0.1 | 1.1 | -10 |
| Menopause | 0.1 | 0 | 0 |
| Metabolic Syndrome | 0.5 | 0.5 | 0 |
| Mood Disorders | 0.2 | 0.2 | 0 |
| Multiple Sclerosis | 0.3 | 0.7 | -1.33 |
| Multiple system atrophy (MSA) | 0 | 0 | 0 |
| myasthenia gravis | 0 | 0 | |
| neuropathic pain | 0.1 | -0.1 | |
| Neuropathy (all types) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.2 | 1 |
| NonCeliac Gluten Sensitivity | 0 | 0 | 0 |
| Obesity | 1.2 | 0.6 | 1 |
| obsessive-compulsive disorder | 0.5 | 0.4 | 0.25 |
| Osteoarthritis | 0.1 | 0 | 0 |
| Osteoporosis | 0 | 0.3 | 0 |
| Parkinson's Disease | 0.8 | 0.4 | 1 |
| Polycystic ovary syndrome | 0.2 | 0 | 0 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| Premenstrual dysphoric disorder | 0 | 0 | |
| primary biliary cholangitis | 0.3 | 0.3 | |
| Primary sclerosing cholangitis | 0.3 | -0.3 | |
| Psoriasis | 0.6 | 0 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 0.4 | 2 |
| Rosacea | 0.1 | 0 | 0 |
| Schizophrenia | 0.2 | 0 | 0 |
| scoliosis | 0.1 | 0.1 | |
| sensorineural hearing loss | 0.1 | 0.1 | |
| Sjögren syndrome | 0.4 | -0.4 | |
| Sleep Apnea | 0.3 | 0 | 0 |
| Slow gastric motility / Gastroparesis | 0 | 0 | |
| Stress / posttraumatic stress disorder | 0.4 | 0 | 0 |
| Systemic Lupus Erythematosus | 0 | 0 | |
| Tic Disorder | 0.4 | -0.4 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.2 | -0.2 | |
| Type 2 Diabetes | 0.5 | 0.4 | 0.25 |
| Ulcerative colitis | 0.3 | 0.4 | -0.33 |
| Unhealthy Ageing | 0.5 | 0 | 0 |
| Vitiligo | 0 | 0.1 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
